Supplemental Table S2. Risk of Repeat Revascularization among Patients Who Have Changed Their Oral Glucose Lowering Agents after the Index Date of PCI

	No.	Repeat PCI	Duration	IR, /1,000 PY	HR (95% CI)				
					Model 1	Model 2	Model 3	Model 4	Model 5
Sulfonylurea									
No	12,938	1,363	55,734.48	24.46	1 (reference)	1 (reference)	1 (reference)	1 (reference)	1 (reference)
Yes	14,942	1,607	66,681.68	24.10	1.00 (0.93–1.08)	1.0 (0.93–1.07)	1.17 (1.06–1.30)	1.17 (1.06–1.30)	1.13 (1.02–1.25)
Metformin									
No	7,656	949	32,746.10	28.98	1 (reference)	1 (reference)	1 (reference)	1 (reference)	1 (reference)
Yes	20,224	2,021	89,670.06	22.54	0.78 (0.72–0.84)	0.78 (0.72–0.84)	0.75 (0.67–0.84)	0.75 (0.67–0.85)	0.79 (0.70–0.88)
Meglitinides									
No	27,358	2,897	120,102.18	24.12	1 (reference)	1 (reference)	1 (reference)	1 (reference)	1 (reference)
Yes	522	73	2,313.98	31.55	1.33 (1.06–1.68)	1.30 (1.03–1.65)	1.22 (0.97–1.54)	1.22 (0.97–1.54)	1.18 (0.93–1.49)
TZD									
No	26,989	2,901	118,407.81	24.50	1 (reference)	1 (reference)	1 (reference)	1 (reference)	1 (reference)
Yes	891	69	4,008.35	17.21	0.70 (0.55–0.89)	0.71 (0.56–0.90)	0.75 (0.59–0.95)	0.75 (0.59–0.95)	0.73 (0.58–0.93)
DPP4i									
No	19,226	2,184	86,257.93	25.32	1 (reference)	1 (reference)	1 (reference)	1 (reference)	1 (reference)
Yes	8,654	786	36,158.23	21.74	0.82 (0.75–0.89)	0.82 (0.76–0.89)	0.86 (0.78–0.95)	0.86 (0.78–0.94)	0.87 (0.79–0.96)
AGI									
No	25,261	2,633	109,856.37	23.97	1 (reference)	1 (reference)	1 (reference)	1 (reference)	1 (reference)
Yes	2,619	337	12,559.79	26.83	1.19 (1.06–1.33)	1.18 (1.06–1.33)	1.29 (1.15–1.46)	1.29 (1.15–1.46)	1.28 (1.14–1.45)

The incidence rate is presented per 1,000 person-years (PY).

Model 1: Adjusted for age and sex; Model 2: Adjusted model 1+adjusted for household income, hypertension, dyslipidemia, current smoking, alcohol, regular exercise, and body mass index; Model 3: Adjusted model 2+adjusted for use of insulin, number of oral antidiabetic drugs; Model 4: Adjusted model 3+adjusted for fasting blood glucose; Model 5: Adjusted model 4+adjusted for duration of diabetes.

PCI, percutaneous coronary intervention; IR, incidence rate; HR, hazard ratio; CI, confidence interval; TZD, thiazolidinedione; DPP4i, dipeptidyl peptidase-4 inhibitor; AGI, alpha glucosidase inhibitor.